Eosinophilic Esophagitis Market Set to Surge as New Research Unveils Breakthrough Treatments | DelveInsight

The dynamics of the eosinophilic esophagitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as APT-1011 (Ellodi Pharmaceuticals), tezepelumab (AstraZeneca,) and ESO-101 (EsoCap) during the forecast period (2024–2034). LAS...